Orforglipron: difference between revisions
Diff·revision 17 → 18·13:59, 28 Sep 2025
Difference between revision 17 and revision 18 of Orforglipron. 2 lines changed; the page grew by 274 bytes.
| Revision 17 — 23:11, 30 Aug 2025 MolarMassMaeve (talk) add the excipient list from the labelling 5,373 bytes ±0 | Revision 18 — 13:59, 28 Sep 2025 RotationRosalind (talk) expand §Reported clinical findings 5,647 bytes +274 | ||
|---|---|---|---|
| 41 | Whether efficacy matches that of the injected peptides at their higher doses is the open question. The phase 2 figures are broadly comparable with [[Semaglutide|semaglutide]] 2.4 mg and below those reported for [[Tirzepatide|tirzepatide]] 15 mg, but cross-trial comparison of this kind is unreliable and the phase 3 programme is the proper test. | 41 | Whether efficacy matches that of the injected peptides at their higher doses is the open question. The phase 2 figures are broadly comparable with [[Semaglutide|semaglutide]] 2.4 mg and below those reported for [[Tirzepatide|tirzepatide]] 15 mg, but cross-trial comparison of this kind is unreliable and the phase 3 programme is the proper test. |
| 42 | 42 | ||
| + | 43 | Orforglipron is a small molecule and does not appear in peptide research-chemical supply in the way the injectable analogues do; material offered under the name would be characterised by small-molecule methods rather than by the peptide battery this wiki mostly describes. | |
| + | 44 | ||
| 43 | == References == | 45 | == References == |
| 44 | {{reflist}} | 46 | {{reflist}} |